Cash management is critical for pharmaceutical companies: The ability to fund drug innovation can make the difference between ...

Alumis shares jump 95% after envudeucitinib meets all endpoints in two phase III plaque psoriasis studies, showing strong skin clearance.

Indian drugmakers primarily produce generics, or copycat versions, and in order to enter the market, they either have to wait ...

Learn more about whether Travere Therapeutics, Inc. or Zymeworks Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Learn more about whether Twist Bioscience Corporation or Zymeworks Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Bristol-Myers Squibb's key drugs are losing patent protection, while more recently launched drugs are struggling to meet peak revenue expectations. Learn more about BMY stock here.

Sandoz Inc. was named in a patent infringement lawsuit on Oct. 23 in New Jersey District Court. The action, brought by Saul Ewing; Quinn Emanuel Urquhart & Sullivan; and Jones Day on behalf of Celgene ...

This article is part of TPM Cafe, TPM’s home for opinion and news analysis. It was originally published at ProPublica, a Pulitzer Prize-winning investigative newsroom. Sign up for The Big Story ...

Press Release Distributed by ABNewswire.com To view the original version on ABNewswire visit: Sjogren’s Syndrome Market Size ...

Celgene, Bristol-Myers Squibb, Teva Pharmaceuticals USA and other drugmakers were hit with an antitrust lawsuit on Oct. 6 in California Northern District Court. The lawsuit was brought by BRS LLP on ...